BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Tsubota A, Satoh KI, Aizawa M, Takamatsu S, Namiki Y, Ohkusa T, Fujise K, Tajiri H. Four-week pegylated interferon α-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized study. World J Gastroenterol 2008; 14(47): 7220-7224 [PMID: 19084937 DOI: 10.3748/wjg.14.7220]
URL: https://www.wjgnet.com/1007-9327/full/v14/i47/7220.htm
Number Citing Articles
1
Yi-Wen Huang, Albert Qin, Chan-Yen Tsai, Pei-Jer Chen. Novel Pegylated Interferon for the Treatment of Chronic Viral HepatitisViruses 2022; 14(6): 1128 doi: 10.3390/v14061128
2
Keizo Kato, Takeshi Yonezawa, Chizuko Tachibana, Hiroyuki Tachibana, Satoshi Watanabe, Yasushi Mandai, Rei Kashima, Kazushi Fukuda. Response-guided therapy based on reaction to the initial dose using administration of peginterferon α-2a alone or in combination with ribavirin in naïve patients with chronic hepatitis C of serotype 2 and high viral loadsKanzo 2012; 53(1): 18 doi: 10.2957/kanzo.53.18